Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin